Weatherman2020
Diamond Member
- Mar 3, 2013
- 93,872
- 65,392
Science is making the vaccines obsolete.
New drug that is what the vaccines are not: Long lasting and effective.
Regeneron Pharmaceuticals today announced the results from a Phase 3 trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), which assessed the use of a single dose of investigational REGEN-COV, a monoclonal antibodies drug, to prevent COVID-19 in uninfected individuals.
The new analyses show REGEN-COV reduced the risk of contracting COVID-19 (i.e., laboratory-confirmed symptomatic SARS-CoV-2 infections) by 81.6% during the pre-specified follow-up period (months 2 - 8 ), maintaining the 81.4% risk reduction during the first month after administration, which was previously reported in The New England Journal of Medicine.
New drug that is what the vaccines are not: Long lasting and effective.
Regeneron Pharmaceuticals today announced the results from a Phase 3 trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), which assessed the use of a single dose of investigational REGEN-COV, a monoclonal antibodies drug, to prevent COVID-19 in uninfected individuals.
The new analyses show REGEN-COV reduced the risk of contracting COVID-19 (i.e., laboratory-confirmed symptomatic SARS-CoV-2 infections) by 81.6% during the pre-specified follow-up period (months 2 - 8 ), maintaining the 81.4% risk reduction during the first month after administration, which was previously reported in The New England Journal of Medicine.
Regeneron says single dose of drug cut risk of COVID-19 by 81.6% – Disclose.tv
Regeneron Pharmaceuticals today announced the results from a Phase 3 trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), which assessed the use of a single dose of investigational REGEN-COV, a monoclonal antibodies drug, to prevent COVID-19 in uninfected...
www.disclose.tv